Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idursulfase - GC Biopharma

Next Previous
Drug Profile

Idursulfase - GC Biopharma

Alternative Names: CAN-101; GC 1123; GC 1123 B; GC-1111; GC1111B; Hunterase; Hunterase ICV; Iduronate-2-sulfatase - GC Biopharma; Idursulfase beta; Idursulfase-beta - GC Biopharma; Recombinant human iduronate-2-sulfatase - GC Biopharma; Recombinant human iduronate-w-sulfatase

Latest Information Update: 13 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Cross
  • Developer CANbridge Pharmaceuticals; GC Biopharma
  • Class Iduronate sulfatases; Recombinant proteins
  • Mechanism of Action Iduronate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis II
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis II

Most Recent Events

  • 30 Jun 2023 Launched for Mucopolysaccharidosis II in Japan (Intracerebral), prior to June 2023 (GC Biopharma pipeline, June 2023)
  • 20 Sep 2022 Phase-I clinical trials in Mucopolysaccharidosis II (In infants, In children, In adolescents, Treatment-experienced) in South Korea (Intracerebral) (NCT05422482)
  • 16 Jun 2022 GC Biopharma plans a phase I trial for Mucopolysaccharidosis II (Hunter Syndrome) (In children, In adults) in South Korea (NCT05422482; GC1123_MPS2_P0101)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top